Literature DB >> 9395383

Risk for gastric lymphoma in persons with CagA+ and CagA- Helicobacter pylori infection.

H L Witherell1, S Hansen, E Jellum, N Orentreich, J H Vogelman, J Parsonnet.   

Abstract

Infection with Helicobacter pylori increases the risk for gastric non-Hodgkin's lymphoma (GNHL). Strains that express CagA protein are thought to be particularly virulent. It was determined whether CagA+ H. pylori infection increased the risk for GNHL more than CagA infection. Thirty-two cases and 130 controls previously tested for H. pylori antibodies were tested for CagA antibodies by ELISA. The risk for GNHL was compared among CagA+, CagA-, and uninfected persons by use of conditional logistic regression. CagA+ subjects had 8.2 times the risk for GNHL than uninfected persons (95% confidence interval [CI], 2.5-26.7). CagA- subjects had 4.4 times the risk for GNHL than uninfected persons (95% CI, 1.2-16.5). Among infected subjects only, CagA+ infection was not associated with significantly increased risk for GNHL when compared with CagA- infection (odds ratio, 2.1; 95% CI, 0.8-5.4). This study does not support a major role for CagA in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395383     DOI: 10.1086/517346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Analysis of vacA, cagA, and IS605 genotypes and those determined by PCR amplification of DNA between repetitive sequences of Helicobacter pylori strains isolated from patients with nonulcer dyspepsia or mucosa-associated lymphoid tissue lymphoma.

Authors:  N E van Doorn; F Namavar; L J van Doorn; Z Durrani; E J Kuipers; C M Vandenbroucke-Grauls
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  [Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy].

Authors:  M Eck; W Fischbach
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

3.  Serum antibody responses to Helicobacter pylori and the cagA marker in patients with mucosa-associated lymphoid tissue lymphoma.

Authors:  A Taupin; A Occhialini; A Ruskone-Fourmestraux; J C Delchier; J C Rambaud; F Mégraud
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

4.  Helicobacter typhlonius sp. nov., a Novel Murine Urease-Negative Helicobacter Species.

Authors:  C L Franklin; P L Gorelick; L K Riley; F E Dewhirst; R S Livingston; J M Ward; C S Beckwith; J G Fox
Journal:  J Clin Microbiol       Date:  2001-11       Impact factor: 5.948

5.  Predictive factors and prevalence of follicular gastritis in adults with peptic ulcer and nonulcer dyspepsia.

Authors:  S D Ladas; T Rokkas; S Georgopoulos; P Kitsanta; C Liatsos; P Eustathiadou; A Karameris; C Spiliadi; S A Raptis
Journal:  Dig Dis Sci       Date:  1999-06       Impact factor: 3.199

Review 6.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT).

Authors:  Masahiro Tajika; Keitaro Matsuo; Hidemi Ito; Dai Chihara; Vikram Bhatia; Shinya Kondo; Tsutomu Tanaka; Nobumasa Mizuno; Kazuo Hara; Susumu Hijioka; Hiroshi Imaoka; Kazuya Matsumoto; Tsuneya Nakamura; Yasushi Yatabe; Kenji Yamao; Yasumasa Niwa
Journal:  J Gastroenterol       Date:  2013-06-25       Impact factor: 7.527

8.  Evaluation of the association of nine Helicobacter pylori virulence factors with strains involved in low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Philippe Lehours; Armelle Ménard; Sandrine Dupouy; Bernard Bergey; Fréderique Richy; Frank Zerbib; Agnès Ruskoné-Fourmestraux; Jean Charles Delchier; Francis Mégraud
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Presence of terminal EPIYA phosphorylation motifs in Helicobacter pylori CagA contributes to IL-8 secretion, irrespective of the number of repeats.

Authors:  Konstantinos S Papadakos; Ioanna S Sougleri; Andreas F Mentis; Efstathios Hatziloukas; Dionyssios N Sgouras
Journal:  PLoS One       Date:  2013-02-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.